Cargando…

Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib

BACKGROUND: Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense for treatment of non-small cell lung cancer (NSCLC). Findings from an ALTER0303 phase III trial revealed that this drug confers significant survival benefits in patients. Alth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Mengqiu, Song, Chao, Zhang, Yaowen, Xu, Xiaoyu, Wang, Chen, Zhang, Zhanchun, Chen, Tian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606049/ https://www.ncbi.nlm.nih.gov/pubmed/34801029 http://dx.doi.org/10.1186/s12944-021-01596-5

Ejemplares similares

Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib
por: Chen, Tian, et al.
Publicado: (2022)

Prognostic value of prognostic nutritional index and its variations in advanced non‐small‐cell lung cancer patients treated with anlotinib monotherapy
por: Chen, Tian, et al.
Publicado: (2022)

Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Factors and Reference Markers of Treatment Options for Locally Advanced Squamous Cell Carcinoma Located in the Middle and Upper Esophagus
por: Wang, Chen, et al.
Publicado: (2021)

Inflammation‐based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy
por: Chen, Tian, et al.
Publicado: (2022)

Predictive value of microvascular density for response to anlotinib in advanced NSCLC
por: Liu, Danqing, et al.
Publicado: (2022)

Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib
por: Liu, Jingjing, et al.
Publicado: (2020)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
por: Wang, Jing, et al.
Publicado: (2018)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
por: Zhou, Jun, et al.
Publicado: (2023)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

Prognostic factors of patients with advanced lung cancer treated with anlotinib: a retrospective cohort study
por: Fan, Bijun, et al.
Publicado: (2021)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

Comparative Clinical Efficacy of ‘Concurrent Chemoradiotherapy (CCRT) and Anlotinib’ Than CCRT in Patients with Locally Advanced ESCC
por: Wang, Gang, et al.
Publicado: (2022)

Implication of VEGFR2 Polymorphism on the Prognosis of Anlotinib Monotherapy for Patients With Treatment-Refractory Advanced NSCLC: An Exploratory Study
por: Li, Xiaoyuan, et al.
Publicado: (2022)

Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report
por: Zhang, Aixia, et al.
Publicado: (2019)

Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor
por: Cheng, Jian-De, et al.
Publicado: (2020)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
por: Wu, Di, et al.
Publicado: (2019)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways
por: Zhu, Zhongling, et al.
Publicado: (2021)

Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A
por: Gu, Guoqing, et al.
Publicado: (2021)

The efficacy and safety of anlotinib treatment for advanced lung cancer
por: Shao, Lan, et al.
Publicado: (2019)

Absolute Neutrophil Count in the Peripheral Blood Predicts Prognosis in Lung Cancer Patients Treated with Anlotinib
por: Chen, Rong, et al.
Publicado: (2021)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report
por: Wang, Jingyi, et al.
Publicado: (2023)

Anlotinib suppresses lung adenocarcinoma growth via inhibiting FASN-mediated lipid metabolism
por: Shen, Juan, et al.
Publicado: (2022)

Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
por: Zhong, Yuejiao, et al.
Publicado: (2020)

Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells
por: Zhu, Zhongling, et al.
Publicado: (2023)

Anlotinib plus chemotherapy for T790M‐negative EGFR ‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial
por: Li, Juan, et al.
Publicado: (2022)

Successful treatment of advanced ovarian cancer with anlotinib: a case report
por: Zhang, Ping, et al.
Publicado: (2020)

Late-stage esophageal neuroendocrine carcinoma in a patient treated with tislelizumab combined with anlotinib: a case report
por: Zhang, Yanqi, et al.
Publicado: (2023)

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
por: Dai, Shuang, et al.
Publicado: (2022)

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line
por: Lu, Jun, et al.
Publicado: (2019)

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
por: Cortellini, Alessio, et al.
Publicado: (2022)

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
por: Li, Ye, et al.
Publicado: (2020)

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature
por: Zhang, Yishi, et al.
Publicado: (2023)

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
por: Huang, Jing, et al.
Publicado: (2021)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Jiang, Fenge, et al.
Publicado: (2022)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Surgical resection following therapy with anlotinib in locally advanced papillary thyroid carcinoma: a case description
por: Zhang, Jing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mpom5p1f5j2uuccjudbbf0s5mb